ACHV Achieve Life Sciences (ACHV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000949858
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
85
13F, latest reported quarter
What the filings say about ACHV
Insiders, 180 days
-$175.2K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$155.1K
1 notice
Achieve Life Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ACHIEVE LIFE SCIENCES, INC. insiders sold a net $175.2K of stock across 13 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Sep 18, 2025.
- +12.2% median (+12.2% mean) 90-day return after 2 previous buys.
- The trade is 9.9% of the 208,249 shares held after it.
- No other insider sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stewart Richard Alistair sold about $175.2K of ACHV on Aug 19, 2026; 85 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 17, 2025.
- The trade is 39.1% of the 127,940 shares held after it.
- 5 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Oki Mark K sold about $146.2K of ACHV on Sep 18, 2025; 5 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 17, 2025.
- +12.2% median (+12.2% mean) 90-day return after 2 previous buys.
- The trade is 56.6% of the 228,875 shares held after it.
- 5 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Stewart Richard Alistair sold about $378.1K of ACHV on Sep 18, 2025; 5 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 43.0% of the 32,694 shares held after it.
- 5 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Wan Jerry sold about $39.0K of ACHV on Sep 4, 2025, the largest insider sale at the company on our record; 5 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 44.4% of the 315,142 shares held after it.
- 5 other insiders sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KING THOMAS BRAXTON sold about $387.4K of ACHV on Sep 4, 2025, the largest insider sale at the company on our record; 5 other insiders sold within 30 days and 85 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$175.2K over 180 days
-$175.2K over 90 days
more than 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
85 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
23.4% of the float short (float per yahoo 2026-10-26) · 10.9 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACHV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+28.0%12M
Insider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACHV: institutional holders (13F)
13F holdings, latest reported quarter
7,614,836 sh
$49.7M
6,877,580 sh
$44.9M
5,914,720 sh
$38.6M
5,425,000 sh
$35.4M
5,272,017 sh
$34.4M
Congress trades in ACHV
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
venBio Global Strategic Fund V, L.P.
Activist 13D · 2026-04-27
9.99%
venBio Global Strategic GP V, LLC
Activist 13D · 2026-04-27
9.99%
TPG GP A, LLC
Activist 13D · 2026-04-24
12.6%
James G. Coulter
Activist 13D · 2026-04-24
12.6%
Jon Winkelried
Activist 13D · 2026-04-24
12.6%
ACHV planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Stewart Richard Alistair
Filed 2026-08-19
$155.1K
ACHV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$9.4M position · as of 2026-06-30
12.1%
Eventide Healthcare & Life Sciences Fund
$14.5M position · as of 2026-06-30
0.8%
Virtus Biotech Clinical Trials Etf
$361.5K position · as of 2026-07-31
0.8%
Franklin Biotechnology Discovery Fund
$7.0M position · as of 2026-07-31
0.6%
iShares Micro-Cap ETF
$1.7M position · as of 2026-06-30
0.1%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$8.8M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
0 active
5
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.5M
$2.2M
$1.1M
+44%
n/a
2023
$1.7M
$1.6M
$1.3M
+68%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $175.2K sold by insiders over 180 days, 85 funds added last quarter, $155.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ACHV financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$37.6M |
| FY Dec 2021 | -$29.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity ACHV
| FY Dec 2025 | 0.52x |
| FY Dec 2024 | 0.47x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.90x |
| FY Dec 2021 | 0.53x |
| Jun 2026 | n/a |
| Mar 2026 | 0.87x |
| Dec 2025 | 0.52x |
| Sep 2025 | 0.26x |
| Jun 2025 | 0.21x |
| Mar 2025 | 0.84x |
| Dec 2024 | 0.47x |
| Sep 2024 | 0.31x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-6.30x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt ACHV
| FY Dec 2025 | -4.42x |
| FY Dec 2024 | -3.03x |
| FY Dec 2023 | -1.51x |
| FY Dec 2022 | -2.38x |
| FY Dec 2021 | -1.97x |
| Jun 2026 | -6.30x |
| Mar 2026 | -4.86x |
| Dec 2025 | -4.42x |
| Sep 2025 | -4.69x |
| Jun 2025 | -4.59x |
| Mar 2025 | -4.11x |
| Dec 2024 | -3.03x |
| Sep 2024 | -2.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-845.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ACHV
| FY Dec 2025 | -257.7% |
| FY Dec 2024 | -409.5% |
| FY Dec 2023 | -869.9% |
| FY Dec 2022 | -233.0% |
| FY Dec 2021 | -101.5% |
| Jun 2026 | -845.0% |
| Mar 2026 | -496.1% |
| Dec 2025 | -257.7% |
| Sep 2025 | -161.1% |
| Jun 2025 | -120.1% |
| Mar 2025 | -154.5% |
| Dec 2024 | -409.5% |
| Sep 2024 | -186.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-91.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ACHV
| FY Dec 2025 | -135.9% |
| FY Dec 2024 | -137.3% |
| FY Dec 2023 | -120.9% |
| FY Dec 2022 | -109.3% |
| FY Dec 2021 | -75.5% |
| Jun 2026 | -91.5% |
| Mar 2026 | -172.0% |
| Dec 2025 | -135.9% |
| Sep 2025 | -104.7% |
| Jun 2025 | -81.5% |
| Mar 2025 | -94.8% |
| Dec 2024 | -137.3% |
| Sep 2024 | -91.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$632.5M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value ACHV
| FY Dec 2025 | $254.8M |
| FY Dec 2024 | $118.1M |
| FY Dec 2023 | $87.9M |
| FY Dec 2022 | $14.8M |
| FY Dec 2021 | $45.4M |
| Jun 2026 | $629.9M |
| Mar 2026 | $137.8M |
| Dec 2025 | $254.8M |
| Sep 2025 | $137.7M |
| Jun 2025 | $35.2M |
| Mar 2025 | $88.3M |
| Dec 2024 | $118.1M |
| Sep 2024 | $163.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -158.0% |
| FY Dec 2021 | -40.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ACHV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M |
| EPS (diluted) | -1.25 | -1.24 | -1.50 | -4.00 |
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M |
| Cash | $20.9M | $12.8M | $15.5M | $24.8M |
| Long-term debt | $11.2M | $9.8M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ACHV Stock Sonar score 5/7 axes
Find similar shapesCompareACHV ranks highest on institutional and government (62nd percentile) and risk and compliance (31st), and lowest on profitability (16th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ACHV filings, in plain words
Are Achieve Life Sciences insiders buying or selling ACHV?
In the 180 days to 2026-10-27, Achieve Life Sciences insiders were net sellers, a net $175.2K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of ACHV?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $155.1K of stock; the latest, by Stewart Richard Alistair, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-27, Achieve Life Sciences insiders were net sellers of ACHV, a net $175.2K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $155.1K of stock. The latest 5% ownership filing is a 13D by venBio Global Strategic Fund V, L.P., filed 2026-04-27, for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
